Sign up to save your podcasts
Or
Share Antigen tolerance in mouse MS model, epileptiform activity and ICU outcomes, agent slows gliomas.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Antigen tolerance in mouse MS model, epileptiform activity and ICU outcomes, agent slows gliomas.
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.
View all episodes
By American Academy of Neurology
4.7
1919 ratings
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.
More shows like Neurology Today in 5
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
322 Listeners
JAMA Clinical Reviews
498 Listeners
Neurology® Podcast
296 Listeners
Practical Neurology Podcast
49 Listeners
JAMA Neurology Author Interviews
13 Listeners
Annals On Call Podcast
191 Listeners
JAMA Medical News
93 Listeners
The Clinical Problem Solvers
514 Listeners
Neurology Minute
136 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
368 Listeners
Neurology Exam Prep Podcast
190 Listeners
The Curious Clinicians
374 Listeners
The Lancet Neurology in conversation with
6 Listeners
Continuum Audio
83 Listeners